Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.

Matthew J. Ellis(Washington University in St. Louis), William R. Miller, F. Jänicke, Erhard Quebe‐Fehling, Andrew Coop, Hilary A. Chaudri‐Ross(Novartis (Switzerland)), Tao Yu(Johns Hopkins University), Baljit Singh, L. Mauriac(Institut Bergonié), Dean B. Evans(Novartis (Switzerland)), Antonio Llombart‐Cussac(Universidad Cardenal Herrera CEU)

PubMed

October 1, 2003

Cited by 202

Related Papers

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

|Journal of Clinical Oncology|2017|1.7k

Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

|Journal of Clinical Oncology|2001|1.1k

Whole-genome analysis informs breast cancer response to aromatase inhibition

|Nature|2012|1k

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

|JAMA Oncology|2019|983

Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

|Journal of Clinical Oncology|2000|840